HR+HER2- - Globe Thesis

Keyword [HR+HER2-] Result: 1 - 15 \| Page: 1 of 1
1.	Metastatic Behaviors And Treatment Strategies Of Hormone Receptor Positive And Human Epidermal Growth Factor Receptor-2 Negative Breast Cancer
2.	Research Progress Of CDK4/6 Inhibitors In HR+,HER2-advanced Breast Cancer
3.	Prognostic Analysis Of Hormone Receptor Positive T1 Stage Breast Cancer And The Establishment Of Prognostic Model
4.	Experiment Study On The Effects Of Trastuzumab Combined With Fulvestrant In HR+/HER2+ Breast Cancer
5.	Omission Of Chemotherapy In HR+/HER2- Early Invasive Breast Cancer Based On Combined 6-IHC Score Compare With 21 Gene Expression Assay
6.	Analysis Of Influencing Factors And Efficacy Prediction Of Neoadjuvant Chemotherapy On HR Positive And HER2 Negative Breast Cancer
7.	Fulvestrant Plus CDK4/6 Inhibitors Or PI3K/mTOR/AKT Inhibitors For HR+/HER2-advanced Breast Cancer That Failed In The First-line Endocrine Therapy:A Meta-analysis
8.	The Ki-67 Cut-off Value In HR+/HER2-breast Cancer And The Different Expression Level With Early Recurrence And Metastasis
9.	HRI Confers Tamoxifen Resistance To HR+HER2-breast Cancer Cells By Activating EIF2A/OAS3/ERα Pathway
10.	Cancer/Testis Antigen MAGEC2 Promotes Resistance To CDK4/6 Inhibitors In HR+/HER2- Breast Cancer By Activating PI3K/AKT/mTOR Pathway
11.	Clinical Study On The Recurrence Risk Of HR+/HER2+ Breast Cancer And The Pathology And Prognosis Of Its Single-hormone Receptor Positive Subtypes
12.	Preliminary Research Of The Existence And Clinical Significance Of Basal Like Sub-cell Population In HR+/HER2-breast Cancer
13.	Impact Of HR,HER2,and Ki-67 Status Conversions On Survival After Neoadjuvant Chemotherapy In Breast Cancer Patients
14.	Long-term Outcomes By Neoadjuvant Efficacy Indexes In HR+ And HR+/HER2+ Breast Cancer:A Systematic Review And Meta-analysis
15.	Mechanism Research Of LGALS3BP In Regulating Sensitive To Adriamycin Therapy Of HR+/HER2-breast Cancer
<<First <Prev Next> Last>> Jump to